At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Labetalol +1 moredrug
Likely dose
Labetalol 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Blood Loss and Visibility With Esmolol vs. Labetalol in Endoscopic Sinus Surgery: A Randomized Trial
The University of Texas Medical Branch, Galveston·interventional·Posted Sep 7, 2018·Updated Feb 8, 2021
In Brief
A Phase 2 clinical trial evaluating Labetalol and Esmolol for Chronic Sinusitis. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The purpose of this study is to compare esmolol and labetalol bleeding and intra-operative visibility scores in functional endoscopic sinus surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Sinusitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
Primary CompletionMar 2018
First PostedSep 2018
TodayJul 2026
First PostedSep 7, 2018
Enrollment StartMar 1, 2017
Primary CompletionMar 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago
Interventions
Labetaloldrug
Aliquots of 20mg of Labetol • Maximum Dose - 300mg total for case
Esmololdrug
Infusion - 0.1mg/kg/min • Maximum Dose - after 30 minutes, 0.3mg/kg/min